Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

ClinicalTrials.gov ID: NCT02890368

Public ClinicalTrials.gov record NCT02890368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Study identification

NCT ID: NCT02890368
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 56 participants

Conditions and interventions

Conditions

Interventions

TTI-621 + PD-1/PD-L1 Inhibitor Drug
TTI-621 + T-Vec Other
TTI-621 + pegylated interferon-α2a Drug
TTI-621 + radiation Other
TTI-621 Monotherapy Drug

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2016
Primary completion: Mar 30, 2020
Completion: Mar 30, 2020
Last update posted: Apr 4, 2023

2016 – 2020

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	—
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15237	—
Inova Schar Cancer Institute	Fairfax	Virginia	22031	—
University of Washington - Seattle Cancer Care Alliance	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02890368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 4, 2023 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02890368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →